Document 0111
 DOCN  M94A0111
 TI    Treatment of oropharyngeal candidiasis in HIV-infected children with
       oral fluconazole.
 DT    9412
 AU    Marchisio P; Principi N; Pediatric Department 4, University of Milan,
       Ospedale Luigi; Sacco, Italy.
 SO    Eur J Clin Microbiol Infect Dis. 1994 Apr;13(4):338-40. Unique
       Identifier : AIDSLINE MED/94349965
 AB    In an open, noncomparative, multicentre study the efficacy and safety of
       oral fluconazole was evaluated in the treatment of oropharyngeal
       candidiasis in children with HIV infection. Fifty-one children with a
       mean age of five years were enrolled. Oropharyngeal candidiasis was
       caused by Candida albicans in 28 cases (55%). Fluconazole was given in a
       mean dosage of 3.4 mg/kg/d (range 2 to 5.6 mg/kg/d) for a mean duration
       of 12 days (range 6 to 28 days). By the end of treatment, 90% of the
       children were clinically cured, 6% had improved and 4% failed to
       respond. Candida was eradicated in 82% of the patients. Clinical failure
       occurred only in children given 3 mg/kg/d or less. Two and four weeks
       after therapy, clinical cure was confirmed in 88% and 82% of the
       children respectively as well as eradication in 76% respectively. Six
       children experienced mild side effects (1 skin rash, 5 mild elevation of
       liver enzyme levels). The data show that fluconazole is safe and
       effective in treating oropharyngeal candidiasis in HIV-infected
       children.
 DE    Administration, Oral  Adolescence  AIDS-Related Opportunistic
       Infections/*DRUG THERAPY  Body Weight  Candida/ISOLATION & PURIF
       Candidiasis, Oral/*DRUG THERAPY  Child  Child, Preschool
       Fluconazole/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE  Human  Infant
       Male  Pharyngeal Diseases/*DRUG THERAPY  CLINICAL TRIAL  JOURNAL ARTICLE
       MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).